XERS vs. VERU, ZEAL, CALT, COLL, ELVN, PRTA, SAVA, ARCT, ARQT, and VRNA
Should you be buying Xeris Biopharma stock or one of its competitors? The main competitors of Xeris Biopharma include Veru (VERU), Zealand Pharma A/S (ZEAL), Calliditas Therapeutics AB (publ) (CALT), Collegium Pharmaceutical (COLL), Enliven Therapeutics (ELVN), Prothena (PRTA), Cassava Sciences (SAVA), Arcturus Therapeutics (ARCT), Arcutis Biotherapeutics (ARQT), and Verona Pharma (VRNA). These companies are all part of the "medical" sector.
Veru (NASDAQ:VERU) and Xeris Biopharma (NASDAQ:XERS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, community ranking, analyst recommendations, institutional ownership, media sentiment, risk and valuation.
Veru received 129 more outperform votes than Xeris Biopharma when rated by MarketBeat users. However, 69.80% of users gave Xeris Biopharma an outperform vote while only 69.59% of users gave Veru an outperform vote.
In the previous week, Xeris Biopharma had 2 more articles in the media than Veru. MarketBeat recorded 5 mentions for Xeris Biopharma and 3 mentions for Veru. Xeris Biopharma's average media sentiment score of 1.01 beat Veru's score of 0.49 indicating that Veru is being referred to more favorably in the media.
Veru presently has a consensus price target of $4.00, suggesting a potential upside of 296.04%. Xeris Biopharma has a consensus price target of $4.63, suggesting a potential upside of 105.10%. Given Xeris Biopharma's higher probable upside, equities research analysts clearly believe Veru is more favorable than Xeris Biopharma.
Veru has a beta of -0.47, indicating that its share price is 147% less volatile than the S&P 500. Comparatively, Xeris Biopharma has a beta of 2.37, indicating that its share price is 137% more volatile than the S&P 500.
Xeris Biopharma has higher revenue and earnings than Veru. Xeris Biopharma is trading at a lower price-to-earnings ratio than Veru, indicating that it is currently the more affordable of the two stocks.
47.2% of Veru shares are owned by institutional investors. Comparatively, 42.8% of Xeris Biopharma shares are owned by institutional investors. 14.2% of Veru shares are owned by insiders. Comparatively, 4.6% of Xeris Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Xeris Biopharma has a net margin of -37.58% compared to Xeris Biopharma's net margin of -265.27%. Xeris Biopharma's return on equity of -130.13% beat Veru's return on equity.
Summary
Veru beats Xeris Biopharma on 9 of the 17 factors compared between the two stocks.
Get Xeris Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for XERS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding XERS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Xeris Biopharma Competitors List
Related Companies and Tools
